Sectors News Results

  • China's Industrial Profit Growth Slowed in April

    China's industrial profit growth slowed in April, official data showed Thursday, as the favorable effect of a lower base last year gradually waned. China's industrial profit grew 57% on year in April, down from March's 92.3% growth, according to the National Bureau of Statistics. Compared with the same month in 2019 before the economy was hit by the coronavirus, industrial profit rose 50.2% in April, 10.7 percentage points higher than March, the bureau said.

  • Tech Stocks Drive Major Indexes Higher as Nasdaq Rises 1.4%-- 2nd Update

    By Anna Hirtenstein and Alexander Osipovich. U.S. stocks advanced Monday, led by rebounding shares of technology and communications companies, as investors grew more comfortable with the inflation outlook and the pace of the economic recovery. The tech-heavy Nasdaq Composite rose 190.18 points, or 1.4%, to 13661.17, adding to its recovery after it eked out a small gain last week and snapped a four-week losing streak.

  • Tech Stocks Drive Major Indexes Higher as Nasdaq Rises 1.4%

    By Anna Hirtenstein and Alexander Osipovich. U.S. stocks advanced Monday, led by rebounding shares of technology and communications companies, as investors grew more comfortable with the inflation outlook and the pace of the economic recovery. The tech-heavy Nasdaq Composite rose 190.18 points, or 1.4%, to 13661.17, adding to its recovery after it eked out a small gain last week and snapped a four-week losing streak.

  • Tech Stocks Drive Major Indexes Higher as Nasdaq Rises 1.4%

    By Anna Hirtenstein and Alexander Osipovich. U.S. stocks advanced Monday, led by rebounding shares of technology and communications companies, as investors grew more comfortable with the inflation outlook and the pace of the economic recovery. The tech-heavy Nasdaq Composite rose 1.4%, adding to its recovery after it eked out a small gain last week and snapped a four-week losing streak.

  • Tech Stocks Drive Major Indexes Higher

    By Anna Hirtenstein and Alexander Osipovich. U.S. stocks advanced Monday, led by rebounding shares of technology and communications companies, as investors grew more comfortable with the inflation outlook and the pace of the economic recovery. The tech-heavy Nasdaq Composite rose 1.6% in afternoon trading, adding to its recovery after it eked out a small gain last week and snapped a four-week losing streak.

  • Stocks, Bitcoin Rebound After Last Week's Turbulence

    By Anna Hirtenstein and Alexander Osipovich. U.S. stocks advanced Monday, led by rebounding shares of technology and communications companies, as investors grew more comfortable with the inflation outlook and the pace of the economic recovery. The tech-heavy Nasdaq Composite rose 1.5% in midday trading, adding to its recovery after it eked out a small gain last week and snapped a four-week losing streak.

  • Stocks Climb; Bitcoin Edges Up From Multi-Month Lows

    U.S. stocks advanced Monday, led by shares of technology and communications companies, as investors grew more comfortable with the inflation outlook and the pace of the economic recovery. The S&P 500 climbed 0.8% in morning trading, an upbeat start to the week after the index declined for two weeks in a row. The Dow Jones Industrial Average gained 165 points, or 0.5%.

  • House Committee Takes on Pricing, Patents for Top-Selling Drug Humira -- 2nd Update

    AbbVie Inc.' s pricing practices for some of its top-selling medicines faced fresh scrutiny from federal lawmakers Tuesday, the latest effort by members of Congress probing the cost of prescription drugs. Democratic members of the U.S. House Committee on Oversight and Reform have been investigating how AbbVie (ABBV) sets the prices of some of its products, including its top-selling immunology drug, Humira.

  • House Committee Takes on Pricing, Patents for Top-Selling Drug Humira -- Update

    AbbVie Inc.' s pricing practices for some of its top-selling medicines faced fresh scrutiny from federal lawmakers Tuesday, the latest effort by members of Congress probing the cost of prescription drugs. Democratic members of the U.S. House Committee on Oversight and Reform have been investigating how AbbVie (ABBV) sets the prices of some of its products, including its top-selling immunology drug, Humira.

  • House Committee Takes on Pricing, Patents for Top-Selling Drug Humira

    AbbVie Inc.' s pricing practices for some of its top-selling medicines are expected to face fresh scrutiny from federal lawmakers Tuesday, the latest effort by members of Congress probing the cost of prescription drugs. Democratic members of the U.S. House Committee on Oversight and Reform have been investigating how AbbVie (ABBV) sets the prices of some of its products, including its top-selling immunology drug, Humira.

Search News

Filter Results

Publication Date
Topic
Provider

News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.